Get the Daily Brief
Latest Biotech News
Pan‑disease blood proteome maps 9,000 samples across 59 conditions
An international team led by SciLifeLab and KTH published a large proteomic survey profiling blood from more than 9,000 individuals spanning 59 diseases using high‑throughput Olink assays. The...
Shuttle Pharma buys Molecule.ai – $10M leap into AI drug discovery
Shuttle Pharmaceuticals submitted a letter of intent to acquire Molecule.ai for $10 million in cash and stock to incorporate the company’s AI models into Shuttle’s drug discovery workflows....
Senate tacks Biosecure Act onto NDAA – industry‑level access limits move forward
The U.S. Senate passed a revised Biosecure Act as an amendment to the National Defense Authorization Act, advancing legislation that would restrict federal funding and contracting with certain...
Novo buys Akero for $4.7B — blockbuster push into MASH
Novo Nordisk reached an agreement to acquire Akero Therapeutics for approximately $4.7 billion in cash, adding the FGF21 analogue efruxifermin to its metabolic pipeline. The deal includes...
BMS buys Orbital for $1.5B — in vivo CAR-T race heats up
Bristol Myers Squibb offered $1.5 billion in cash to acquire Orbital Therapeutics, a start‑up developing in vivo CAR‑T approaches, according to reports. The acquisition brings Orbital’s lead...
Partial pig liver transplant supports human patient…then removed
A Chinese surgical team reported transplanting a genetically modified pig liver segment into a human patient with a hepatic tumor, documenting 38 days of graft support before removal due to...
Sarepta to seek LGMD gene therapy approval — first in class possible
Sarepta Therapeutics presented data showing its experimental gene therapy raised expression of the missing gene in limb‑girdle muscular dystrophy type 2E (LGMD2E) and announced plans to file for...
Senate passes Biosecure Act as NDAA amendment — supply chain rules shift
The U.S. Senate approved a new iteration of the Biosecure Act as an amendment to the National Defense Authorization Act for FY2026. The revised bill seeks to restrict federal funding or...
Pan‑disease blood proteome map...a 9K‑sample resource for biomarkers
An international consortium led by SciLifeLab and KTH published a large‑scale proteomic atlas profiling ~9,000 blood samples across 59 diseases using Olink Explore/Explore HT platforms and made...
Epigenetic editing cuts PCSK9, slashes LDL in primates
Researchers delivered an mRNA‑based epigenetic editor targeting PCSK9 to nonhuman primate livers and reported durable reductions in PCSK9 expression and LDL cholesterol for nearly a year after a...
Illumina’s genomic alliance draws pharma partners — target discovery ramp
Illumina expanded its Alliance for Genomic Discovery partnerships, adding Alnylam Pharmaceuticals and attracting pharma interest in large, linked genomic‑clinical datasets from biobanks such as...
Altos Labs tests anti‑aging biology in perfused organs — ex vivo platform advances
Altos Labs disclosed work testing rejuvenation therapies in organs maintained ex vivo, advancing its program to evaluate anti‑aging interventions outside the body. The company is reportedly using...
Head of FDA orphan drug office reassigned — orphan pathways face scrutiny
The director of the FDA Office that oversees orphan drug designations was removed from the role and reassigned, an administrative official confirmed. Sandra Retzky’s reassignment affects the...
BMS buys Orbital for $1.5B: in vivo CAR‑T push
Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in cash to add in vivo CAR‑T capabilities to its pipeline. The deal brings Orbital’s lead program, OTX‑201, and its...
Novo buys Akero — shutters cell therapy unit: strategy pivot
Novo Nordisk announced the acquisition of Akero Therapeutics for $4.7 billion to secure efruxifermin, an FGF21 analogue in late‑stage development for metabolic dysfunction‑associated...
Gene editing bets deepen: Mammoth trial planned — epigenetic PCSK9 edit shows durable LDL cuts
Mammoth Biosciences disclosed preclinical primate data for its lead gene‑editing program and signaled plans to move toward first‑in‑human testing of a triglyceride‑lowering editing approach, while...
Part of pig liver transplanted into human…functioned for 38 days
Chinese surgeons transplanted a genetically modified pig liver segment into a patient with an inoperable tumor and reported the graft supported metabolic functions for 38 days before removal, with...
Sarepta to file for LGMD gene therapy: first treatment in rare disease class
Sarepta Therapeutics presented data showing its experimental gene therapy increased expression of the missing gene in limb girdle muscular dystrophy 2E (LGMD2E) and said it plans to file for...
FDA orphan drug office chief reassigned: internal leadership shift
The director of the FDA office that oversees orphan drug designations was removed from the role and reassigned, an administration official confirmed to Endpoints News. Sandra Retzky’s reassignment...
Senate passes Biosecure Act — new limits on certain biotech ties
The U.S. Senate passed a revised Biosecure Act as an amendment to the National Defense Authorization Act, authorizing restrictions on federal funding or contracting with designated 'biotechnology...